Your browser doesn't support javascript.
loading
Mapping Drug Dose Distribution on CT Images Following Transarterial Chemoembolization with Radiopaque Drug-Eluting Beads in a Rabbit Tumor Model.
Mikhail, Andrew S; Pritchard, William F; Negussie, Ayele H; Krishnasamy, Venkatesh P; Amchin, Daniel B; Thompson, John G; Wakim, Paul G; Woods, David; Bakhutashvili, Ivane; Esparza-Trujillo, Juan A; Karanian, John W; Willis, Sean L; Lewis, Andrew L; Levy, Elliot B; Wood, Bradford J.
  • Mikhail AS; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Pritchard WF; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Negussie AH; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Krishnasamy VP; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Amchin DB; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Thompson JG; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Wakim PG; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Woods D; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Bakhutashvili I; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Esparza-Trujillo JA; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Karanian JW; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Willis SL; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Lewis AL; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Levy EB; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
  • Wood BJ; From the Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center (A.S.M., W.F.P., A.H.N., V.P.K., D.B.A., J.G.T., D.W., I.B., J.A.E.T., J.W.K., E.B.L., B.J.W.), National Institute of Biomedical Imaging and Bioengineering (B.J.W.), National Cancer Institute Center for
Radiology ; 289(2): 396-404, 2018 11.
Article en En | MEDLINE | ID: mdl-30106347
ABSTRACT
Purpose To correlate bead location and attenuation on CT images with the quantity and distribution of drug delivered to the liver following transarterial chemoembolization (TACE) with radiopaque drug-eluting beads (DEB) in a rabbit tumor model. Materials and Methods All procedures were performed with a protocol approved by the Institutional Animal Care and Use Committee. TACE was performed in rabbits (n = 4) bearing VX2 liver tumors by using radiopaque DEB (70-150 µm) loaded with doxorubicin (DOX). Livers were resected 1 hour after embolization, immediately frozen, and cut by using liver-specific three-dimensional-printed molds for colocalization of liver specimens and CT imaging. DOX penetration into tissue surrounding beads was evaluated with fluorescence microscopy. DOX levels in liver specimens were predicted by using statistical models correlating DOX content measured in tissue with bead volume and attenuation measured on CT images. Model predictions were then compared with actual measured DOX concentrations to assess the models' predictive power. Results Eluted DOX remained in close proximity (<600 µm) to beads in the liver 1 hour after TACE. Bead volume and attenuation measured on CT images demonstrated positive linear correlations (0.950 and 0.965, respectively) with DOX content in liver specimens. DOX content model predictions based on CT images were accurate compared with actual liver DOX levels at 1 hour. Conclusion CT may be used to estimate drug dose delivery and distribution in the liver following transarterial chemoembolization (TACE) with doxorubicin-loaded radiopaque drug-eluting beads (DEB). Although speculative, this informational map might be helpful in planning and understanding the spatial effects of TACE with DEB. © RSNA, 2018.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Doxorrubicina / Tomografía Computarizada por Rayos X / Quimioembolización Terapéutica / Neoplasias Hepáticas / Antibióticos Antineoplásicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Doxorrubicina / Tomografía Computarizada por Rayos X / Quimioembolización Terapéutica / Neoplasias Hepáticas / Antibióticos Antineoplásicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals Idioma: En Año: 2018 Tipo del documento: Article